Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Leukemia, Myeloid, Acute 104Multiple Myeloma 66Lymphoma 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Myelodysplastic Syndromes 51Lymphoma, Non-Hodgkin 51Leukemia 50Hodgkin Disease 42Lymphoma, Mantle-Cell 29Lymphoma, Large B-Cell, Diffuse 29Leukemia, Lymphocytic, Chronic, B-Cell 26Leukemia, Myelogenous, Chronic, BCR-ABL Positive 23Lymphoma, Follicular 22Burkitt Lymphoma 22Breast Neoplasms 22Recurrence 20Neoplasms, Plasma Cell 18Neuroblastoma 17Hematologic Neoplasms 17Lymphoma, B-Cell, Marginal Zone 15Myeloproliferative Disorders 14Lymphoma, Large-Cell, Immunoblastic 14Leukemia, Myelomonocytic, Chronic 12Leukemia, Biphenotypic, Acute 12Congenital Abnormalities 12Blast Crisis 10Anemia, Refractory, with Excess of Blasts 10Retinoblastoma 9Central Nervous System Neoplasms 9Sarcoma 8

Interventions

Cisplatin 7Etoposide 6Amifostine 6Radiotherapy 5Drug Therapy 5Cyclophosphamide 5apatinib 4Methotrexate 4Filgrastim 4Cytarabine 4sodium thiosulfate 3Methylprednisolone 3Carboplatin 3pegfilgrastim 2glucarpidase 2etoposide phosphate 2Voriconazole 2Vincristine 2Social Determinants of Health 2Pyridoxine 2Nivolumab 2Gemcitabine 2Doxorubicin 2Docetaxel 2Chemotherapy, Adjuvant 2Capecitabine 2trastuzumab deruxtecan 1selinexor 1sargramostim 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Drug-Related Side Effects and Adverse Reactions × Granulocyte Colony-Stimulating Factor × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡